Categories: US FDA Approval

Zydus Cadila gets USFDA nod to market two drugs

 Ahmedabad January 10, 2014: Ahmedabad-based firm has also received USFDA approval to market Duloxetine delayed release capsules in different strengths

Ahmedabad-based  received the final approval from the US drug regulator to market one immuno-supressant and one anti-depressant drug in the US market.

Zydus today informed that it received the nod to market Sirolimus tablets of strength 0.5 mg with 180 days of marketing exclusivity, together with the nod to market Duloxetine delayed release capsules in different strengths of 20 mg, 30 mg and 60 mg.

As per IMS data  the sales of  Sirolimus 0.5mg  was estimated at $11.7 million and the total market for Sirolimus was approximately $203.8 million in 2013. The sales for Duloxetine was estimated at $5.5 billion in 2013.

While Sirolimus tablets are immuno-suppressant  used to prevent rejection in organ transplantation, Duloxetine delayed release capsules fall in the anti-depressants segment.

The group now has 86 approvals and has so far filed 216 ANDAs since the commencement of filing process in FY 2003-04.

Earlier in 2013, the company had received  nods for a number of other drugs. Zydus had received the phase one clinical trial approval from the USFDA for ZYDPLA1, a novel next generation new chemical entity that would offer once a week oral treatment option for Type-2 diabetic patients in October 2013. In August, the company had  received the final approval from the USFDA to market Lansoprazole DR Capsules in different strengths of  15 mg and 30 mg.-Business Standard 

The Pharma Times News Bureau

Recent Posts

DKMS-BMST – Bridging the Care Gap in Blood Cancer Treatment on National Cancer Awareness Day

New Delhi, November 07, 2024: National Cancer Awareness Day serves as a poignant reminder of…

14 hours ago

The Arya Vaidya Pharmacy (Coimbatore) Ltd. Strengthens Legacy with New Initiatives and Expanded Product Portfolio

Coimbatore, November 07, 2024: The Arya Vaidya Pharmacy (Coimbatore) Ltd. (AVP), a pioneer in Ayurvedic…

14 hours ago

New medical nutrition ingredient combines high-protein with “best taste yet”

New Delhi, November 06, 2024: Arla Foods Ingredients has launched a new whey protein hydrolysate…

1 day ago

6 Early Signs of Ovarian Cancer

By Dr. C N Patil, HOD and Lead Consultant - Medical Oncology & Haemato-Oncology, Aster…

1 day ago

Bayer Introduces Bepanthen in India as New Survey Reveals Dry Skin Affects 1 in 2 Indians

·        World's no.1 skincare brand Bepanthen* launches in India, as a solution to tackle India's widespread dry skin…

2 days ago

Lung Cancer in India: Understanding Risk Factors and the Importance of Early Detection

By Dr. Pavan Yadav, Lead Consultant - Interventional Pulmonology & Lung Transplantation, Aster RV Hospital.…

3 days ago